Aspira pathlab & Diagnostics Limited has filed its mandatory compliance certificate with BSE Limited for the quarter ended March 31, 2026. The submission, dated April 14, 2026, fulfills the company's regulatory obligations under SEBI (Depositories and Participants) Regulations, 2018.

Regulatory Compliance Filing

The compliance certificate was submitted pursuant to regulation 74(5) of the SEBI (Depositories and Participants) regulations, 2018. The document was signed by Pankaj Shah, Managing Director of Aspira Pathlab & Diagnostics Limited, and forwarded to the Listing Department of BSE Limited.

Registrar Confirmation

MUFG Intime India Private Limited, formerly known as Link InTime India Private Limited, serves as the company's Registrar & Share Transfer Agent. The firm issued the compliance certificate on April 3, 2026, confirming adherence to prescribed procedures for handling dematerialised securities.

The registrar's certificate confirms several key compliance aspects:

• Securities received from depository participants for dematerialisation during the quarter were properly confirmed to depositories
• All securities comprised in certificates have been listed on stock exchanges where earlier issued securities are listed
• Security certificates received for dematerialisation were confirmed or rejected within prescribed timelines
• Received certificates were mutilated and cancelled after due verification by depository participants
• Names of depositories were substituted in the register of members as registered owners

Company Information

Aspira Pathlab & Diagnostics Limited operates with its registered office located at Flat No. 2, R D Shah Building, Shraddhanand Road, Opp. Railway Station, Ghatkopar (W), Mumbai-400086. The company's corporate office is situated at 6 & 7, Bhaveshwar Arcade, Near Shreyas Junction LBS Marg, Behind Saraswat Bank, Ghatkopar (W), Mumbai-400086.

The filing represents routine regulatory compliance, ensuring transparency and proper governance in the handling of shareholder securities and maintaining adherence to SEBI guidelines for depositories and participants.

Aspira pathlab & Diagnostics Limited has officially set March 27, 2026 as the record date for its upcoming open offer under SEBI takeover regulations. The announcement was made by Aftertrade Broking Private Limited, the manager for the open offer, in compliance with Securities and Exchange Board of India regulations.

Open Offer Details

The open offer encompasses significant parameters for public shareholders of the target company:

Acquirer Information

The open offer involves five primary acquirers working collectively to acquire the stake in Aspira Pathlab & Diagnostics Limited. The acquirer group includes Mr. Arvind Karsandas Bhanushali, Mrs. Deepali Arvind Bhanushali, Mr. Jay Arvind Bhanushali, Mr. Nikunj Velji Mange, and Mr. Raj Arvind Bhanushali. Additionally, Mrs. Shraddha Nikunj Mange is participating as a Person Acting in Concert (PAC) with the acquirers.

Regulatory Timeline

The open offer process has followed a structured timeline in accordance with SEBI regulations:

• Public Announcement: September 26, 2025
• Detailed Public Statement: Published in newspapers on October 6, 2025
• Draft Letter of Offer: October 13, 2025
• Record Date Announcement: March 25, 2026
• Identified Record Date: March 27, 2026

Management and Compliance

Aftertrade Broking Private Limited, registered with SEBI under registration number INM000013110, is serving as the manager for this open offer. The company has confirmed that the March 27, 2026 date will determine the names of shareholders who will receive the Letter of Offer. This compliance measure aligns with regulation 18(2) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeover) Regulations, 2011.

The announcement was signed by Vanesh Panchal, Director of Aftertrade Broking Private Limited, with DIN 06944544, ensuring proper authorization and regulatory compliance for the open offer process.